

NZX RELEASE

10 Birch Street PO Box 5804 Dunedin 9058 New Zealand

Telephone: 03 474 1338 Fax: 03 474 9050 Email: info@blis.co.nz Website: www.blis.co.nz

2nd May 2018

Blis Technologies achieves another international regulatory milestone

Blis Technologies Ltd (NZX: BLT) announces that it has achieved another significant international regulatory milestone with its oral probiotic called BLIS M18® by obtaining GRAS status, which now enables this probiotic to be included as an ingredient in food products within the United States.

The US Food and Drug Administration (FDA) requires all ingredients used in food manufacturing to obtain a standard for safety, which is referred to as GRAS (Generally Recognised As Safe).

The GRAS procedure follows an FDA-regulated process which allows a company to obtain GRAS status through consultation with an independent panel of world leading experts in disciplines such as microbiology and toxicology. The Expert Panel concluded that generally available data pertinent to the safety BLIS M18® probiotic meets the FDA's stringent criteria for safety, and therefore was concluded to be Generally Recognized as Safe.

CEO Brian Watson said "The BLIS M18® GRAS status represents another regulatory milestone for our unique oral probiotics, and this follows on from the strong regulatory status of BLIS K12®. This approval further strengthens our pipeline of new market opportunities and will be well received by US-based customers."

Brian Watson Chief Executive

Contact: +64 27 705 9133